Immatics Biotechnologies Granted U.S. Patent #11685769: Peptides for use in immunotherapy against cancers
Portfolio Pulse from Charles Gross
Immatics Biotechnologies has been granted U.S. Patent #11685769 for peptides used in immunotherapy against cancers. This patent could potentially strengthen the company's position in the cancer immunotherapy market.
June 27, 2023 | 9:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immatics Biotechnologies' new patent for cancer immunotherapy peptides may boost the company's position in the market and attract investor interest.
The granted patent for peptides used in immunotherapy against cancers could potentially enhance Immatics Biotechnologies' product portfolio and increase its competitiveness in the market. This may lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100